This proposal presents, for synthesis and pharmacological evaluation, series of 2-aminoindans, enantiomers of alpha-ethyltryptamines, certain benzofuran congeners, and [125I]-labeled analogs of the novel psychoactive agent 3,4-methylenedioxymethamphetamine (MDMA). Structures are based upon our previous findings that certain alpha- ethylphenethylamines and rigid analogs of MDMA possess animal behavioral pharmacology similar to MDMA, but have attenuated dopaminergic properties and decreased serotonin neurotoxicity. The target structures will serve as pharmacological tools for several purposes: to aid in elucidation of the mechanism of action of MDMA, to further refine the structure-activity relationships of MDMA-like drugs, to study certain components of the neurotoxic effects of MDMA-like agents, and to be used to help elucidate the role of serotonin in certain behavioral states. In particular, following synthesis, new compounds will be tested for MDMA-like behavioral pharmacology using the two-lever drug discrimination paradigm, in rats trained to discriminate saline form the alpha-ethyl homolog of MDMA,(+)-MBDB. Compounds which fully substitute will then be examined for ability to inhibit uptake or effect release of serotonin (5-HT), dopamine, or norepinephrine from rat brain synaptosomes. Compounds showing high selectivity for 5-HT will be further evaluated for acute in vivo effects on brain monoamine and metabolite levels. After multiple dosing with these compounds and sacrifice at 1-week, examination of brain monoamines, their metabolites, and radioligand binding parameters using the 5-HT uptake inhibitor [3H]- paroxetine, will be used as indicators of serotonin neurotoxic potential. Compounds will be evaluated for reinforcing properties using the conditioned place preference paradigm. Compounds which do not induce place preference will be tested for their ability to antagonize (+)-amphetamine-induced place conditioning, as potential antagonist of the reinforcing properties of psychostimulants. Formal collaborative arrangements have been developed with five other laboratories to study further new compounds for locomotor activating effects in rats, ability to increase extracellular dopamine measured by in vivo microdialysis, and the radiosynthesis and use of certain neurotoxic and nonneurotoxic [125I]-ligands to visualize 5-HT neurons in rat brain. Also through a collaborative arrangement, compounds that block amphetamine-induced place preference will be tested for an ability to antagonize the reinforcing effects of cocaine in rats that intravenously self- administer cocaine.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Project (R01)
Project #
Application #
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Purdue University
Schools of Pharmacy
West Lafayette
United States
Zip Code
Selken, Jennifer; Nichols, David E (2007) Alpha1-adrenergic receptors mediate the locomotor response to systemic administration of (+/-)-3,4-methylenedioxymethamphetamine (MDMA) in rats. Pharmacol Biochem Behav 86:622-30
Kanthasamy, A; Sprague, J E; Shotwell, J R et al. (2002) Unilateral infusion of a dopamine transporter antisense into the substantia nigra protects against MDMA-induced serotonergic deficits in the ipsilateral striatum. Neuroscience 114:917-24
Sprague, J E; Worst, T J; Haynes, K et al. (2001) The pharmacodynamic characterization of an antisense oligonucleotide against monoamine oxidase-B (MAO-B) in rat brain striatal tissue. Cell Mol Neurobiol 21:53-64
Sprague, J E; Everman, S L; Nichols, D E (1998) An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19:427-41
Parker, M A; Marona-Lewicka, D; Kurrasch, D et al. (1998) Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA). J Med Chem 41:1001-5
Marona-Lewicka, D; Nichols, D E (1998) Drug discrimination studies of the interoceptive cues produced by selective serotonin uptake inhibitors and selective serotonin releasing agents. Psychopharmacology (Berl) 138:67-75
Cozzi, N V; Frescas, S; Marona-Lewicka, D et al. (1998) Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential. Pharmacol Biochem Behav 59:709-15
Marona-Lewicka, D; Nichols, D E (1997) 5-HT2A/2C receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat. Neuropharmacology 36:1471-5
Marona-Lewicka, D; Rhee, G S; Sprague, J E et al. (1996) Reinforcing effects of certain serotonin-releasing amphetamine derivatives. Pharmacol Biochem Behav 53:99-105
Sprague, J E; Nichols, D E (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther 273:667-73

Showing the most recent 10 out of 30 publications